Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Niagen Bioscience ( (NAGE) ) has shared an update.
On December 16, 2025, Niagen Bioscience’s subsidiary ChromaDex, Inc. entered into an assignment agreement with Queen’s University Belfast that replaced earlier joint ownership and licensing deals and transferred QUB’s entire interest in a core portfolio of NR-related patents to the company. In exchange, Niagen agreed to structured payments including a one-time sum of about $1 million for accrued royalties through 2024, recurring annual payments from 2026 to 2038, and additional lump-sum payments in 2035 and 2038, while QUB provided a broad release from past royalty and other obligations. Announced publicly on December 22, 2025, the transaction makes Niagen the sole owner of foundational composition-of-matter and related patents covering the production, composition, and global commercial use of NR and its salt forms, consolidating what the company describes as the most comprehensive and defensible intellectual property position in the NAD+ industry and giving it greater financial, strategic and operational flexibility in developing, partnering and licensing its NAD+ precursor pipeline, including potential pharmaceutical applications.
The most recent analyst rating on (NAGE) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.
Spark’s Take on NAGE Stock
According to Spark, TipRanks’ AI Analyst, NAGE is a Outperform.
Niagen Bioscience’s overall stock score is driven by strong financial performance and positive corporate events, indicating robust growth potential. However, bearish technical indicators and a moderate valuation temper the outlook. The earnings call further supports a positive future trajectory, despite some regulatory challenges.
To see Spark’s full report on NAGE stock, click here.
More about Niagen Bioscience
Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is a global leader in NAD+ science and healthy-aging research, developing NAD+-boosting solutions centered on its patented nicotinamide riboside (NR) ingredient. Its clinically proven portfolio includes the consumer supplement Tru Niagen, billed as the leading NAD+ boosting oral supplement in the U.S., and Niagen Plus, a line of pharmaceutical-grade intravenous and injectable NR products supplied through FDA-registered outsourcing facilities for use in clinics by prescription.
Average Trading Volume: 1,019,487
Technical Sentiment Signal: Buy
Current Market Cap: $520.3M
For an in-depth examination of NAGE stock, go to TipRanks’ Overview page.